Valiant Laboratories
VALIANTLAB NSE
Valiant Laboratories
HealthcareNSE: VALIANTLAB BSE: 543998 Pharmaceuticals & Biotechnology
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹644 Cr
Volatility
High Risk
P/E Ratio
43.51
EBITDA
₹6.39 Cr
Return on Equity
-0.94%
Debt to Equity
0.15
Book Value
₹57.24
52W High
₹125.82
52W Low
₹49.51
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has reduced debt.
- Company is expected to give good quarter
Weaknesses
1- Company has a low return on equity of -1.41% over last 3 years.
Growth Rate
Revenue Growth
71.09% higher than
3Y
Net Income Growth
-60.45% higher than
3Y
Cash Flow Change
-30.69% higher than
3Y
ROE
-823% lower than
3Y
ROCE
77.27% higher than
3Y
EBITDA Margin (Avg.)
393% higher than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 60 | 41 | 31 | 19 | 21 | 35 | 58 | 47 | 46 | 52 | 92 | 115 |
| Expenses | 48 | 61 | 47 | 35 | 21 | 28 | 35 | 54 | 44 | 46 | 53 | 87 | 86 |
| Operating Profit | 4 | -1 | -6 | -5 | -2 | -7 | 1 | 4 | 2 | 0 | -1 | 5 | 29 |
| OPM % | 7% | -2.3% | -16% | -15% | -13% | -31% | 1.8% | 7% | 5% | 0.2% | -1.7% | 5% | 25% |
| Other Income | 2 | 3 | 2 | 2 | 3 | 3 | 2 | -2 | 1 | 1 | 1 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 |
| PBT | 6 | 1 | -5 | -3 | 0 | -4 | 2 | 1 | 2 | 0 | -3 | 1 | 26 |
| Tax % | 26% | 25% | -31% | -52% | 219% | 21% | -44% | 26% | 26% | 25% | 136% | -68% | 19% |
| Net Profit | 4 | 1 | -4 | -1 | -1 | -5 | 2 | 1 | 2 | 0 | -7 | 2 | 21 |
| EPS in Rs | 1.05 | 0.19 | -0.64 | -0.23 | -0.09 | -0.87 | 0.43 | 0.13 | 0.34 | 0.04 | -1.3 | 0.32 | 3.88 |
Profit & Loss
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 334 | 182 | 133 | 237 | 306 |
| Expenses | 299 | 190 | 138 | 231 | 273 |
| Operating Profit | 35 | -8 | -5 | 6 | 33 |
| OPM % | 11% | -4.6% | -3.5% | 2.7% | 11% |
| Other Income | 5 | 10 | 5 | 2 | 3 |
| Interest | 0 | 0 | 0 | 2 | 3 |
| Depreciation | 2 | 2 | 2 | 6 | 8 |
| PBT | 38 | -1 | -2 | 1 | 25 |
| Tax % | 24% | -142% | 46% | 525% | — |
| Net Profit | 29 | 0 | -2 | -3 | 16 |
| EPS in Rs | 7.13 | 0.06 | -0.41 | -0.6 | 2.94 |
| Div. Payout % | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 33 | 43 | 43 | 54 |
| Reserves | 68 | 193 | 191 | 257 |
| Borrowings | 60 | 77 | 122 | 46 |
| Other Liabilities | 52 | 29 | 45 | 107 |
| Total Liabilities | 213 | 343 | 401 | 464 |
| Fixed Assets | 48 | 50 | 48 | 227 |
| CWIP | 1 | 43 | 156 | 6 |
| Investments | 34 | 38 | 0 | 28 |
| Other Assets | 130 | 212 | 197 | 202 |
| Total Assets | 213 | 343 | 401 | 464 |
Cash Flow
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | 56 | 2 | 1 | -10 |
| Investing | -55 | -144 | -53 | 7 |
| Financing | -1 | 152 | 45 | 2 |
| Net Cash Flow | 0 | 10 | -7 | -1 |
| Free Cash Flow | 18 | -44 | -112 | -45 |
| CFO/OP | 185 | -11 | 25 | -147 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 97 | 92 | 197 | 144 |
| Inventory Days | 17 | 22 | 13 | 84 |
| Days Payable | 62 | 56 | 128 | 174 |
| Cash Conversion Cycle | 52 | 57 | 82 | 54 |
| Working Capital Days | 70 | 106 | 156 | 156 |
| ROCE % | — | -2% | -1% | 1% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Valiant Laboratories insights
29 extracted metrics + investor summaries across FY23–FY26.
Documents
1
Board Meeting Intimation for Approval Of Financial Results For Quarter And Year Ended March 31, 2026
11h - Board meeting on May 14, 2026 to approve audited Q4 and FY26 standalone and consolidated results. 11h - Board meeting on May 14, 2026 to approve audited Q4 and FY26 standalone and consolidated results.
2
Announcement under Regulation 30 (LODR)-Change in Management
23 Apr - Q.C Manager Bhanudas D. Patil resigned effective April 22, 2026. 23 Apr - Q.C Manager Bhanudas D. Patil resigned effective April 22, 2026.
3
Announcement under Regulation 30 (LODR)-Change in Management
12h - Q.C Manager Bhanudas D. Patil resigned effective April 22, 2026. 12h - Q.C Manager Bhanudas D. Patil resigned effective April 22, 2026.
4
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Apr - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026; all securities held in demat form. 13 Apr - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026; all securities held in demat form.
Frequently Asked Questions about Valiant Laboratories
What does Valiant Laboratories Ltd do?
Incorporated in 1980, Valiant Laboratories
Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]
Where is Valiant Laboratories Ltd (VALIANTLAB) listed?
Valiant Laboratories Ltd trades as VALIANTLAB on the NSE and under code 543998 on the BSE.
Which sector does Valiant Laboratories Ltd belong to?
Valiant Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Valiant Laboratories Ltd?
Valiant Laboratories Ltd has a market capitalisation of ₹643.93 Cr, which places it in the Small Cap band.
What is the PE ratio of Valiant Laboratories Ltd?
Valiant Laboratories Ltd trades at a PE ratio of 43.51, against a book value of ₹57.24 per share.
What is the 52-week high and low of Valiant Laboratories Ltd?
Over the last 52 weeks Valiant Laboratories Ltd has traded between ₹49.51 and ₹125.82.
What is the Return on Equity (ROE) of Valiant Laboratories Ltd?
Valiant Laboratories Ltd reported a return on equity of -0.94%. Its debt-to-equity ratio is 0.15.
Company Information
Incorporated in 1980, Valiant Laboratories Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VALIANTLAB.md for Valiant Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.